Zenas BioPharma, Inc. Balance Sheet
ZBIO / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Zenas BioPharma, Inc. had $384M in total assets and $242M in shareholders' equity as of FY2025. Total debt was $79M against $111M in cash, resulting in a $32M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash & Equivalents | $110.6M | $319.7M | $56.9M |
| Current Assets | $351.2M | $355.9M | $59.8M |
| PP&E (Net) | $34.0K | $185.0K | $193.0K |
| Total Assets | $383.6M | $370.0M | $68.2M |
| Current Liabilities | $62.6M | $57.3M | $23.3M |
| Total Debt | $78.6M | - | - |
| Shareholders' Equity | $242.1M | -$225.7M | -$225.7M |